Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant.

ABSTRACT: The emergence of SARS-CoV-2 variants of concern (VOCs) have diminished the effectiveness of vaccines and are associated with a rebound in the number of COVID-19 cases globally. These variants contain mutations at the spike (S) protein receptor binding site (RBD), which affect antibody binding. Current commercially available antibody assays were developed before the VOCs emerged. It is unclear whether the levels of these commercially available antibody assays can predict the neutralizing antibody titers against the VOCs. In this study, we sought to determine the correlation between the binding antibody concentration and microneutralization antibody titer against the beta variant. This study included 58 COVID-19 patients. The concentrations of IgG against the SARS-CoV-2 spike protein RBD and

SUBMITTER: Poon RW 

PROVIDER: S-EPMC8700542 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature